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Purpose: Quantification of tumour heterogeneity in PET images has recently gained interest, 
but has been shown to be dependent on image reconstruction. This study aimed to evaluate 
the impact of the EANM/EARL accreditation program on selected 18F-FDG heterogeneity 
metrics. 
Methods: Seventy-one tumours in sixty biopsy-proven lung cancer patients acquisitions 
reconstructed with unfiltered PSF PET images (optimized for diagnostic purposes), PSF-
reconstructed images with a 7mm Gaussian filter (PSF7) chosen to meet EANM 1.0 
harmonizing standards, and EARL-compliant OSEM images were prospectively included. 
Delineation was performed with FLAB algorithm on PSF images and reported on PSF7 and 
OSEM ones, and with a 50% SUVmax threshold applied independently to each image. Robust 
and reproducible heterogeneity metrics including 1st-order [area under the curve of the 
cumulative histogram (CHAUC)], 2
d-order (entropy, correlation and dissimilarity) and 3rd-order 
[high intensity larger area emphasis (HILAE) and zone percentage (ZP)] textural features 
(TF) were statistically compared.   
Results: Volumes obtained with 50% SUVmax threshold were significantly smaller than 
FLAB-derived ones, and were significantly smaller in PSF images compared to OSEM and 
PSF7 ones. PSF-reconstructed images showed significantly higher SUVmax and SUVmean 
values, as well as heterogeneity for CHAUC, dissimilarity, correlation and HILAE, and a wider 
range of heterogeneity values than OSEM images for most of the metrics considered, 
especially when analysing larger tumours. Histological subtypes had no impact on TF 
distribution.  
No significant difference was observed between any of the metrics considered (SUV or 
heterogeneity features) extracted from OSEM and PSF7 reconstructions. Furthermore, the 
distributions of TF for OSEM and PSF7 reconstructions according to tumour volumes were 
similar for all ranges of volumes.  
Conclusion: PSF reconstruction with Gaussian filtering chosen to meet harmonizing 
standards resulted in similar SUV values and heterogeneity information, compared to OSEM 
images, which validates its use within the harmonization strategy context. However, 
unfiltered PSF-reconstructed images also showed higher heterogeneity according to some 
metrics, as well as a wider range of heterogeneity values than OSEM images, for most of the 
metrics considered, especially when analysing larger tumours. This suggests that, whenever 
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available, unfiltered PSF images should also be exploited to obtain the most discriminative 
quantitative heterogeneity features. 
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Using quantitative parameters extracted from the Positron Emission Tomography (PET) 
component of PET/Computed Tomography (CT) images, such as Standardized Uptake Values 
(SUV), as biomarkers in multicentre trials or in sites equipped with multiple PET/CT scanners 
requires that these parameters be comparable among patients, regardless of the PET/CT 
system used. This can be achieved by harmonizing patient preparation, as well as data 
acquisition, reconstruction and processing, including the image analysis and parameters 
extraction steps [1-3]. The American college of Radiology (ACR) program [4], the 
EANM/EARL accreditation program [5] and the SNM clinical trials network (SNM-CTN) [6] 
have set up harmonization programs based on the use of phantoms acquisitions. These are 
used as standardized objects in order to harmonize data acquisition, processing and analysis 
so that the physical, technical and biological sources of error [1, 7] in SUV measurements can 
be limited.  
A specific issue is related to reconstruction-dependent variations encountered with recently 
introduced advanced image reconstruction algorithms such as those incorporating the point 
spread function (PSF) in the system matrix [8], or Bayesian penalised likelihood (BPL) 
reconstruction [9]. These new image reconstruction schemes have been shown to produce 
SUV metrics significantly higher than conventional ordered subset expectation maximization 
(OSEM) algorithms [10]. Consequently, an additional filtering step can be used in order to 
meet harmonizing standards [11-13]. With regards to the EANM/EARL program [5], a set of 
PET images with NEMA NU-2 anthropomorphic phantom-based filtering is mandatory to 
harmonize SUVs to the EANM standards. Given that centres running PET systems with 
advanced reconstruction algorithms are often willing to use them with parameters chosen in 
order to achieve optimal lesion detection, EARL-accredited centres tend to use two PET 
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datasets when participating in multicentre trials: one for optimal lesion detection and image 
interpretation, and the filtered one for harmonized quantification [12].  
However, it is important to emphasize that all these previous efforts have been focused on 
usual SUV metrics, as they are commonly used in oncology for therapy assessment and risk 
stratification. However, there is growing interest in using alternative measurements, for 
instance metabolically active tumour volume (MATV) and heterogeneity metrics, in order to 
provide a more comprehensive quantitative assessment of lesions from PET images [14, 15]. 
One of the most promising approaches for heterogeneity quantification is textural features 
analysis, introduced for image processing applications in the 70’s, used in MRI and CT since 
the early 90’s and more recently in PET [16]. As PSF reconstruction improves resolution and 
therefore provides higher definition of structures within a lesion, it is reasonable to expect 
improved evaluation of tumour heterogeneity as compared to OSEM algorithms. This raises 
the question of which reconstruction should be used for assessing tumour heterogeneity 
within a program using a smoothed dataset to reach harmonizing standards. Two studies have 
already reported on the impact of the type of reconstruction algorithm or variation of 
reconstruction parameters on the textural features values [17, 18]. However, they have mostly 
been focused on reporting the quantitative impact only, and have neither explored the issue 
within the context of harmonization programs nor the relationship between heterogeneity and 
volume, an important aspect recently demonstrated [19]. 
This study focused on lung cancer, a tumour type for which standard SUV metrics have been 
proved to be clinically useful [20-23] and for which quantification of tumour heterogeneity in 
PET images has recently gained interest [24, 25] and aimed at evaluating the potential impact 
of the EARL accreditation program [5] on selected 18F-FDG heterogeneity metrics. The 
primary aim was to compare several heterogeneity features previously identified as reliable 
(robust and repeatable) in lung cancer patients, in PSF-reconstructed images, PSF-
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reconstructed images with a filter chosen to meet harmonizing standards and in EARL 
compliant OSEM images, later referred as to OSEM images. This comparison was performed 
not only in terms of absolute values but also in terms of their distributions with respect to 
tumour volume, which was not considered in previous studies. A secondary aim was to study 
whether potential differences in heterogeneity features amongst these three reconstructions 
would be similar in adenocarcinomas (ADC), squamous cell carcinomas (SqCC), and large 




Materials and methods 
 
Patients’ selection 
Over a 3-month period, 60 consecutive biopsy proven lung cancer patients (4 small-cell lung 
cancer and 56 NSCLC) were prospectively included. Informed consent was waived for this 
type of study by the local ethics committees (Ref A12-D24-VOL13, Comité de protection des 
personnes Nord-Ouest III) since the scans were performed for clinical indications and the 
study procedures were performed independently of usual clinical reporting.   
 
PET calibration and cross calibration 
The calibration of the PET system was performed daily with a 68Ge cylinder with a known 
radioactive concentration.  
The cross-calibration procedure was performed twice during the present study, as per the 
EANM guidelines [11]. Details regarding this cross-calibration can be found elsewhere [12]. 
The cross-calibration factors were found to be 0.99 and 1.00.  
 
PET/CT examinations 
After a 15-min rest in a warm room, patients who had been fasting for 6 h were injected with 
18F-FDG. The injected activity and the exact delay between injection and the start of the 
acquisition were recorded for each patient. 
All PET imaging studies were performed on a Biograph TrueV (Siemens Medical Solutions) 
with a 6-slice spiral CT component. For additional technical details regarding this system we 
refer to a previous publication [26]. CT acquisition was performed first, with the following 
parameters: 60 mAs, 130 kVp, pitch 1 and 6 × 2 mm collimation. Subsequently, the PET 
 8 
emission acquisition was performed in 3-D mode. Patients were scanned from the skull base 
to the mid-thighs. 
 
PET reconstruction 
The standard reconstruction in the department where patients were recruited is a PSF 
reconstruction algorithm (HD; TrueX, Siemens Medical Solutions; 3 iterations and 21 
subsets) without filtering. For the purpose of the present study, raw data were also 
reconstructed with the OSEM reconstruction algorithm (4 iterations and 8 subsets) and a PSF 
reconstruction algorithm (HD; TrueX, Siemens Medical Solutions; 3 iterations and 21 
subsets) with a 7 mm Gaussian filter (PSF7). As shown in a previous study, this latter 
reconstruction leads to protocol-specific images with NEMA NU-2 phantom-based filtering 
that meet EANM quantitative harmonizing standards, therefore reducing reconstruction-
dependent variation in SUVs [12]. The OSEM reconstruction parameters met the EANM 
requirements regarding activity recovery. 
For all reconstructions, matrix size was 168 × 168 voxels, resulting in isotropic voxels of 




PET tumour delineation 
All lesions were first automatically delineated in the PSF PET image using the Fuzzy Locally 
Adaptive Bayesian (FLAB) algorithm, and resulting segmentations were reported on the two 
other images (OSEM and PSF7). This process avoided any variability in the tumour volumes 
definition and number of voxels involved in the calculations when comparing features across 
the three images. FLAB has been developed specifically for PET image segmentation [27] 
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and has been thoroughly validated for reproducibility, robustness and repeatability [28, 29], as 
well as for accuracy on simulated and clinical images [30]. Tumours were first located and 
isolated in a volume of interest (VOI) well enclosing the tumour and its surrounding 
background, without including nearby pathological uptake. This was performed using in-
house software in which points are placed by the user around the tumour (see supplemental 
Fig. 1). The FLAB algorithm was then applied to this VOI in fully automated mode, in 
contrast to a semi-supervised approach considered in a previous work on FLT images during 
radiotherapy, in which the contrast and signal-to-noise ratio were lower [31]. 
However, in order to be more representative of a current multicentric clinical setting, tumour 
volumes were also defined using a fixed threshold at 50% of SUVmax (T50) applied 
independently to each of the three images. Furthermore, for the most discordant volumes 
between PSF7/OSEM and PSF (outliers located above the 90th percentile) when using T50, 
tumours were also segmented independently with FLAB on each image.  
Features were then extracted from each of the three volumes and compared. 
 
Tumour characterization and quantification 
From the FLAB-delineated volumes, all “standard” metrics were extracted: SUVmax, SUVmean 
and metabolically active tumour volume. To characterize uptake heterogeneity, several 
metrics were considered: on the one hand, a first-order metric based on the intensity 
histogram (IH) [16] denoted area under the curve of the cumulative histogram (CHAUC) [32]. 
On the other hand, second- and third-order textural features (TF). The metric CHAUC is based 
on intensity histogram only and does not incorporate spatial information. TF have been 
defined to quantify patterns of spatial arrangements and/or intensity variations. There exist 
dozens of TFs based on different computational frameworks. In the present work, we used 
only a few selected TFs. This selection was based on several previous studies showing that 
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most of the features (including first-order metrics such as skewness), especially third-order 
metrics focusing on small areas and/or low intensities, are unreliable due to poor robustness 
vs. reconstruction [17, 18] or partial volume effects and segmentation [33], and low 
reproducibility on test-retest images [34]. The remaining features are either calculated from 
co-occurrence (2nd order, entropy, correlation and dissimilarity) or size-zone matrices [3rd 
order, high intensity larger area emphasis (HILAE) and zone percentage (ZP)]. Before 
building these matrices, images are first discretized into a chosen number of bins (B) with a 
quantization step. It has been shown that the choice of the quantization value (usually 
between 8 and 256) has an important impact on the resulting TF value, but also 
reproducibility [34] or complementary value with the tumour volume in which it is calculated 
[19]. Based on these previous results, a value of B=64 was used in the present work, and the 
quantization was performed using equation 1 in which I(x) is the original SUV of the voxel of 
interest and SUVmin and SUVmax are the minimal and maximal SUV value within the tumour 
volume. 





For co-occurrence matrices, it has been shown that less redundant features are obtained when 
calculated using a single co-occurrence matrix taking into account all 13 spatial directions 
simultaneously, rather than computing a matrix for each direction followed by averaging [19, 
35]. A single co-occurrence matrix was thus adopted in the present work.  
 
Noise analysis in PET images 
In order to evaluate noise characteristics of each of the three reconstructions, signal-to-noise 
ratio (SNR, defined as 20 × log10 (
𝜇
𝜎
)𝐷𝐵 [36] where µ and σ are the mean and standard 
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deviation of intensities) was measured in circular regions of interest placed in homogeneous 
regions of the liver and automatically reported in each reconstruction. 
 
Statistical analysis  
Quantitative data are presented as mean (standard deviation), as well as the median when not 
normally distributed. Bland-Altman analyses were used to compare the SUV metrics obtained 
in the three images. The features obtained on each of the three sets of PET images were first 
compared globally using Friedman tests. Graphical plots of each feature depending on tumour 
volume were also used to estimate the impact of PSF reconstruction compared to OSEM and 
PSF7 images, and the features were then compared by categories of volumes using Friedman 
tests. MATV, SUVmax and TFs extracted from the three sets of data were compared according 
to the histological type of the tumour (ADC, ScCC and LCC) using Kruskal-Wallis tests. For 
all tests, a two-tailed P value of less than 0.05 was considered statistically significant. Graphs 





Population characteristics and compliance to guidelines for tumour imaging 
Population characteristics are displayed in table 1. Overall, 58 (96.7%) patient examinations 
fulfilled the EANM 2.0 guidelines for PET tumour imaging. The mean (SD) injected dose of 
18F-FDG was 4.02 (0.16) MBq/kg. The mean (SD) delay between the injection and the start of 
the PET acquisition was 60.43 (3.38) min. The mean (SD) blood glucose level was 1.04 
(0.23) mmol/L. 
 
Validation of the use of an additional harmonized PET dataset to overcome reconstruction-
dependency of SUVs 
Overall, 71 pulmonary lesions were delineated. The mean (SD, median) FLAB-derived 
MATV was 31.7 (46.4, 9.7) cm3. The mean (SD) SUVmax for OSEM, PSF and PSF7 
reconstructions were 10.50 (5.85), 15.42 (9.56) and 10.56 (5.88) respectively. The mean (SD) 
SUVmean for OSEM, PSF and PSF7 reconstructions were 6.14 (2.99), 7.37 (4.03) and 6.25 
(2.98) respectively. 
As shown in the supplemental Fig. 2, Bland-Altman analysis demonstrated that the mean ratio 
of PSF and OSEM reconstructions for SUVmax and SUVmean were 1.46 (95%CI = 0.86 – 2.08) 
and 1.19 (95%CI = 0.71 – 1.67) respectively. When using the PSF7 harmonized 
reconstruction, the mean ratio between PSF7 and OSEM reconstructions were 1.01 (95%CI = 
0.93 – 1.09) and 1.02 (95%CI = 0.95 – 1.09) for SUVmax and SUVmean respectively. 
Compared to OSEM, SNR in the liver was lower in PSF images (-25.8 ± 3.9 %) whereas it 
was very similar in PSF7 images (1.2 ± 2.9 %). 
 
Impact of newest reconstruction algorithms on textural features 
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In a first step we used FLAB to delineate lesions in PSF images and we reported this 
segmentation on OSEM images. For the first-order metric CHAUC based on the intensity 
histogram, most tumours were quantified as significantly more heterogeneous in PSF images 
compared to OSEM images, as PSF values were significantly lower than OSEM ones (a lower 
area under the curve indicating higher heterogeneity). Regarding second-order metrics 
calculated on the co-occurrence matrix (entropy, correlation and dissimilarity), on the one 
hand, PSF values were significantly lower for correlation and significantly higher for 
dissimilarity (in both cases indicating higher heterogeneity), compared to OSEM 
reconstruction. On the other hand, no significant difference between PSF and OSEM images 
was observed for entropy. Regarding third-order metrics calculated on size-zone matrices 
(HILAE and ZP), there was a significant difference between PSF and OSEM images only for 
HILAE values, which were lower, indicating higher heterogeneity. Fig. 1 displays TFs for the 
three reconstructions used. 
Heterogeneity features were also analysed depending on the range of tumour volumes. As 
shown in Fig. 2, the dispersion of the values (represented by the interquartile range) was 
larger and calculated values were significantly smaller for PSF reconstruction as compared to 
OSEM reconstruction, for tumour volumes larger than 1 cm3 in the case of CHAUC. For 
HILAE, calculated values were also significantly smaller for tumour volumes larger than 1 
cm3 but the dispersion of values was narrower for PSF compared to OSEM. Dissimilarity 
values were significantly higher in PSF for volumes > 50 cm3 and the dispersion of these 
values was larger in PSF images for tumour volumes larger than 1 cm3, compared to OSEM 
reconstruction. Distributions for all metrics can be seen in details in the supplemental Fig. 3 
and Fig. 4. 
When defining volumes using T50 applied independently to OSEM and PSF images, mean 
(median, SD) MATV were significantly smaller on PSF images 9.0 (12.4, 3.3) cm3 as 
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compared to OSEM ones 18.8 (24.2, 7.3) cm3 (p<0.0001). There were significant 
differences between PSF and OSEM images for first-order, second-order and third-order 
metrics with the same trends above detailed (Fig. 3). Fig.  4 displays representative examples 
of tumour delineation using the FLAB algorithm and a 50% of SUVmax threshold, as well as 
the related SUV and TF metrics. 
When comparing volumes obtained with T50 on PSF to OSEM and PSF7 ones, 8 outliers 
(above the 90th percentiles) were observed and re-processed by independently contouring with 
FLAB. There was no significant difference between PSF and OSEM mean (median, SD) 
MATV 12.8 (12.2, 4.8) cm3 and 13.4 (13.0, 4.8), respectively (+5.3±4.6%). There were 
significant differences between PSF and OSEM images for first-order, second-order and 
third-order metrics as previously described, except for dissimilarity and ZP for which there 
were only trends (Supplemental Fig. 5). 
 
Effect of the harmonization strategy on textural features 
In the previous section, using the FLAB algorithm to delineate lesions, we found that data 
extracted from OSEM reconstruction were different from those extracted from PSF 
reconstruction for several TFs but also for CHAUC. When comparing these metrics extracted 
from OSEM and PSF7 reconstructions, none exhibited significant differences (Fig. 1). 
Furthermore, the distributions of their values according to MATV were much more similar for 
all ranges of volumes (Fig. 2) with no significant difference whatever range of tumour 
volumes was considered (except for HILAE in volumes larger than 50 cm3), highlighting that 
the quantifiable heterogeneity content of the PSF7 images was very close to the one contained 
in OSEM images. 
We also defined tumour volumes using T50 applied independently to OSEM and PSF7 
images. When using this methodology, no significant difference was observed between 
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MATV, CHAUC and all TFs extracted from OSEM and PSF7 reconstructions (Fig. 3). Mean 
(SD, median) MATV were 18.8 (24.2, 7.3) cm3 and 19.5 (25.5, 7.7) cm3 for OSEM and PSF7 
reconstruction respectively (ns).  
Analyzing the 8 outliers described above for which FLAB was used independently on the 
three sets of images, there was no difference between OSEM and PSF7 mean (median, SD) 
MATV 13.4 (13.0, 4.8) cm3 and 13.6 (13.2, 5.11) respectively, +1.0±3.4% and between 
textural features extracted from OSEM and PSF7 images (Supplemental Fig. 5). 
 
SUV metrics and heterogeneity features amongst the histological subtypes 
Standard metrics exhibited significant differences amongst the three NSCLC histological 
subtypes. In particular, there was a trend towards smaller volumes in ADC. SUVmax values 
were also different in the three subtypes, with however large overlaps between the three 
distributions. SUVmax values obtained in PSF reconstructed images were higher for all three 
subtypes, resulting however in a similar and unchanged differentiation between them: ADC 
had significantly lower SUVmax than SqCC and LCC in all three reconstructions (Fig. 5). 
Although the heterogeneity metrics were differently distributed with the three different 
reconstruction schemes, none of them were significantly different among the three 






Heterogeneity metrics, especially textural features, have gained interest in the past few years 
to quantify intratumour heterogeneity in PET images. There have been several studies 
highlighting the dependency of these metrics to various factors, including the image analysis 
workflow (such as tumour delineation or partial volume effects correction) [33], the image 
reconstruction schemes or parameters [17, 18], and basic stochastic effects occurring in the 
PET acquisition process [37]. 
Our results confirm some of these previous results regarding the impact of the reconstruction 
choices on these metrics values [18]. Compared to OSEM images, unfiltered PSF-
reconstructed images showed lower signal-to-noise ratio in the liver, higher heterogeneity and 
higher range of heterogeneity values in the tumour, for most of the metrics when using FLAB 
(independently on the three sets of images or not) and for all of the metrics considered in the 
present work when using T50, to be more representative of a current multicentric clinical 
setting. This difference was logically especially observed when analysing larger tumours. Our 
study indeed sheds light on the impact of reconstruction algorithms on the distributions of 
heterogeneity features with respect to tumour volume, which had not been considered in these 
previous studies. Regarding the differences observed in the case of T50, it should be 
emphasized that part of these can be directly attributed to the fact that this segmentation 
method applied to PSF images led to significantly smaller volumes than on OSEM and PSF7 
images, with sometimes drastically reduced volumes not covering the tumour uptake spatial 
extent (see Fig. 4c and 4d and supplemental Fig. 6). This method which has been evaluated 
previously mostly on standard non-PSF images is thus clearly not appropriate to extract 
tumour volume and associated metrics from PSF-reconstructed images because of their higher 
contrast. This also strengthens our approach of using a single volume for more accurate and 
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rigorous comparison of the three images content in terms of textural patterns, to avoid any 
bias in the calculation of TF due to different volumes. 
Thus, the impact of reconstruction for comparable tumour volumes was found to be 
significant for some metrics (CHAUC, correlation, dissimilarity, HILAE) and only an 
observable trend for others (entropy, ZP), and the differences increased with larger tumour 
volumes (for instance in the case of ZP, differences were significant only for tumours larger 
than 50 cm3). This suggests that PSF-based reconstruction may provide more quantifiable 
heterogeneity-related information in larger tumours than OSEM images, as the interval 
between smallest and highest values increases, thereby providing more potential for 
differentiating different levels of heterogeneity in these tumours. Our results also highlight the 
fact that some TFs seem more sensitive than others to the changes in PSF-reconstructed 
images compared to OSEM images when analysing similar volumes determined with FLAB: 
CHAUC, correlation and HILAE showed higher sensitivity with larger differences in both 
overall and volume-related distributions than entropy, dissimilarity and ZP. 
The present study was conducted within the overall harmonization strategy context and 
focused on the EARL accreditation program, which is why unfiltered PSF images (optimized 
for diagnostic purposes) and OSEM images were compared to PSF images filtered with a 7 
mm Gaussian filter chosen to meet the EANM 1.0 guidelines (PSF7). As previously published 
[12], the use of PSF7 resulted in signal-to-noise ratio in the liver and SUVmax values in the 
tumour very close to OSEM, and the same pattern was observed for heterogeneity metrics. All 
metrics considered in the present study were very close with no significant differences when 
extracted from OSEM and PSF7 images, whatever the delineation technique used. This 
suggests that OSEM and PSF7 EARL compliant images present a similar quantifiable 
heterogeneity content, and validates the use of TFs extracted from PSF-filtered images for 
multicentre studies. However, as stated above, our results also suggest that using unfiltered 
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PSF-based reconstructions could provide potentially more discriminative image features 
allowing for higher differentiation amongst patients, for studies aiming to quantify tumour 
heterogeneity using TFs and exploit these metrics for a clinical endpoint, such as patient 
stratification according to survival or response to therapy. Of note, these studies have been 
mostly performed in single sites, but future validation studies will likely require pooling data 
from several centres in order to obtain larger cohorts with enough statistical power. This 
raises the issue of using filtered-harmonized PSF images so that they can be pooled with 
OSEM data from other centres (potentially losing some discriminative power from TFs), or 
pooling data only from centres using PSF reconstruction with no post-filtering. This issue is 
problematic, as the EARL accreditation program is not meant to exclude images from centres 
running PET systems not equipped with PSF reconstruction or other advanced algorithms. 
Also, the sensitivity of TFs to reconstruction parameters needs to be interpreted in the context 
of an important reconstruction disparity within PET centres, even in centres running the same 
PET system, as recently reported by the Clinical Trials Network of the SNMMI [38]. Taken 
together, these findings suggest that PSF reconstruction with a Gaussian filtering chosen to 
meet harmonizing standards could be used within the harmonization strategy context for 
studies aiming to quantify intra-tumour heterogeneity to stratify, rank or classify patients with 
respect to a given clinical endpoint. In addition, we recommend that whenever available, 
unfiltered PSF images should also be analysed, especially for large, single-centre series since 
quantitative metrics obtained from these could potentially offer higher discriminative power. 
This of course requires additional studies in larger cohorts to be demonstrated.  
One limitation of our study is the inclusion of a single system where the underlying 
reconstruction was identical apart from the use of the PSF modeling. Differences in image 
reconstruction methods between several vendors may give rise to additional variability that 
needs to be evaluated before texture analysis could be reliably used in the context of 
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multicentric studies, despite the demonstrated repeatability and robustness of several features 
versus changes in image properties [17, 18, 39]. 
Finally, we sought to identify differences in heterogeneity features within NSCLC 
histological subtypes. Although we showed that the ADC presented much lower volumes as 
well as lower SUVmax values than the SqCC and LCC subtypes, none of the heterogeneity 
metrics showed any discriminative power in differentiating these subtypes, in either 
reconstruction method used, which is in line with recent results obtained in breast cancer [40]. 
On the other hand, it contradicts another recent study that suggested textural features could 
differentiate between ADC and SqCC in a cohort of 30 NSCLC Asian patients [41]. These 
results were obtained on 2D-slice –not 3D volume analysis only, and required the 
combination of numerous parameters through machine learning (automated clustering) in 
order to differentiate the two subtypes. The derived model was not validated in an external 
cohort. This possibly led to overfitting and the results might not be generalizable to other 
series of patients, especially European ones. Our results suggest that heterogeneity features 
could be used in a multicentre setting regardless of the histology in series of European 
patients. Indeed, results in term of heterogeneity in Asian patients may not be applicable to 
European patients, as not only the ratio between ADC and SqCC is inverted in these 
populations, but also the rate of EGFR mutation is higher in Asian patients (20-40%) 
compared to European patients (around 10%) [42]. One could therefore postulate different 
TFs in ADC depending on the mutation status. Studies with a larger ADC population, 
focusing on the differences in heterogeneity features between mutated and non-mutated ADC 





The use of PSF reconstruction with Gaussian filtering chosen to meet harmonizing standards 
produced comparable SUV values, as well as similar levels of heterogeneity information, 
compared to OSEM images, which validates its use within the harmonization strategy context 
for studies aiming to quantify intra-tumour heterogeneity to stratify, rank or classify patients. 
However, unfiltered PSF-reconstructed images showed significantly higher heterogeneity for 
CHAUC, correlation and HILAE, as well as a wider range of heterogeneity values than OSEM 
ones, for most of the metrics considered, especially when analysing larger tumours. This 
suggests that, whenever available, unfiltered PSF images should also be analysed because 
resulting quantitative heterogeneity features could be more discriminative in stratifying or 
ranking patients, which remains to be demonstrated. Finally, the main NSCLC histological 
subtypes in this cohort did not show any differences in terms of intra-tumour heterogeneity, 
despite some notable differences in metabolically active tumour volume and levels of uptake 
(SUVmax). This may facilitate the potential multicentre use of heterogeneity features 
regardless of the histology in series of European patients. 
  
 21 
Compliance with ethical standards 
 
Conflicts of interest none to declare 
 
Ethical approval All procedures performed in studies involving human participants were in 
accordance with the ethical standards of the institutional and/or national research committee 
and with the 1964 Helsinki declaration and its later amendments or comparable ethical 
standards. 
 
Informed consent Informed consent was waived for this type of study by the local ethics 
committee (Ref A12-D24-VOL13, Comité de protection des personnes Nord-Ouest III), since 
the PET scans were performed for clinical indications and the trial procedures were 
performed independent of usual clinical reporting. 
  
 22 
Acknowledgments: Dr Alison Johnson is thanked for proofreading of the manuscript.  
 23 
 




Sex ratio (M/F) 3.13 
Age (years)  
     Range 37 – 90 
     Mean (SD) 64 (10.7) 
Body habitus, n (%)  
     BMI≤25 38 (63.3) 
     BMI>25 22 (36.7) 
Histological diagnosis, n (%)  
     Small cell lung cancer 4 (6.7) 
     Non-small cell lung cancer 56 (93.3) 
          Squamous cell carcinoma  28 (50.0) 
          Adenocarcinoma  21 (37.5) 
          Large cell lung cancer  7 (12.5) 






Fig.  1: Impact of the EARL harmonization strategy on textural features using the 
FLAB algorithm to delineate lesions 
Textural features for the three reconstructions used. CHAUC: area under the curve of the 
cumulative histogram; high intensity larger area emphasis (HILAE); ZP: zone percentage. 
Data is shown as Tukey boxplots (lines displaying median, 25th and 75th percentiles; cross 
represents the mean value).*, **, and *** indicate two-tailed P < .05, P < .01, and P < .001, 
respectively. ns : non significant 
 
Fig.  2: Impact of tumour volume on textural features 
Textural features used for the three reconstructions, depending on tumour volume. CHAUC: 
area under the curve of the cumulative histogram; high intensity larger area emphasis 
(HILAE); ZP: zone percentage. Data is shown as Tukey boxplots (lines displaying median, 
25th and 75th percentiles; cross represents the mean value).*, **, and *** indicate two-tailed 
P < .05, P < .01, and P < .001, respectively. ns: non significant 
 
Fig.  3: Impact of the EARL harmonization strategy on textural features using a 50% of 
SUVmax threshold to delineate lesions 
Textural features for the three reconstructions used. CHAUC: area under the curve of the 
cumulative histogram; high intensity larger area emphasis (HILAE); ZP: zone percentage. 
Data is shown as Tukey boxplots (lines displaying median, 25th and 75th percentiles; cross 





Fig.  4: Representative examples of lung tumours. 
OSEM, PSF and PSF7 images and textural features are displayed for a 67-year old male 
patient with a squamous cell carcinoma (panels a and c) and for a 44-year old female patient 
with an adenocarcinoma (panels b and d). Images have been scaled on the same maximum 
value. Note the improvement in tumour apparent activity and contrast in PSF images 
compared to OSEM images, and the similarity between OSEM and PSF7 images. This can 
also be observed quantitatively in the extracted SUV and TF metrics. Green contours (panels 
a and b) denote the tumour delineation using the automatic Fuzzy Locally Adaptive Bayesian 
(FLAB) algorithm on the PSF image and reported on the two other datasets. Red contours 
(panels c and d) denote the delineation using the 50% of SUVmax threshold applied 
independently to each image. CHAUC: area under the curve of the cumulative histogram; 
high intensity larger area emphasis (HILAE); ZP: zone percentage. 
 
Fig.  5: Standard quantification metrics 
FLAB-derived metabolically active tumour volume (MATV) and standardized uptake values 
(SUVs) according to the histological subtypes (adenocarcinoma:ADC; squamous cell 
carcinoma:SqCC; large cell carcinoma:LCC) in non-small cell lung cancer patients for the 
three reconstructions used. Data is shown as Tukey boxplots (lines displaying median, 25th 
and 75th percentiles; cross represents the mean value). * and ** indicate two-tailed P < .05, 
and P < .01, respectively. ns: non significant. 
 
Fig.  6: Impact of the histological subtype on textural features in non-small cell lung 
cancer patients 
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FLAB-derived textural features according to the histological subtypes (adenocarcinoma: 
ADC; squamous cell carcinoma: SqCC; large cell carcinoma: LCC) in non-small cell lung 
cancer patients for the three reconstructions used. CHAUC: area under the curve of the 
cumulative histogram; high intensity larger area emphasis (HILAE); ZP: zone percentage. 
Data is shown as Tukey boxplots (lines displaying median, 25th and 75th percentiles; cross 
represents the mean value). 
 
Supplemental Fig. 1 
Illustration of the in-house software used to define a 3D box around the tumor, aiming at 
enclosing the tumor as well as excluding any nearby physiological or undesired uptake. For 
details see the materials and methods section. 
 
Supplemental Fig. 2 
Relationship between quantitative values extracted from PSF or PSF7 and OSEM images, 
assessed using Bland-Altman plots for SUVmax (a) and SUVmean (b) in tumour lesions. 
 
Supplemental Fig. 3 
Plots of TF features (CHAUC: area under the curve of the cumulative histogram; high 
intensity larger area emphasis (HILAE); ZP: zone percentage) against tumours MATV for 
OSEM versus PSF reconstructions. 
 
Supplemental Fig. 4 
Plots of TF features (CHAUC: area under the curve of the cumulative histogram; high 
intensity larger area emphasis (HILAE); ZP: zone percentage) against tumours MATV for 
OSEM versus PSF7 reconstructions. 
 27 
Supplemental Fig. 5: Impact of the EARL harmonization strategy on textural features using 
the FLAB algorithm independently on the three sets of reconstructions to delineate lesions 
Textural features for the three reconstructions used. CHAUC: area under the curve of the 
cumulative histogram; high intensity larger area emphasis (HILAE); ZP: zone percentage. 
Data is shown as Tukey boxplots (lines displaying median, 25th and 75th percentiles; cross 
represents the mean value).*, **, and *** indicate two-tailed P < .05, P < .01, and P < .001, 
respectively. ns : non significant. Data represent the 8 outliers (above the 90th percentiles) 
observed with OSEM-PSF MATV and/or PSF7-PSF MATV when using a 50% of SUVmax 
threshold. 
 
Supplemental Fig. 6 
PET transverse slice of a PSF-reconstructed image showing one of the largest differences in 
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